E-Mail Alert

Add your e-mail address to receive forthcoming issues of this journal:

Journal Browser

Journal Browser

Special Issue "Bioactive Compounds for Metabolic Syndrome and Type 2 Diabetes-II"

A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".

Deadline for manuscript submissions: 30 January 2019

Special Issue Editor

Guest Editor
Dr. Béla Juhász

Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, University of Debrecen, Nagyerdei krt. 98, H-4032 Debrecen, Hungary
Website | E-Mail
Interests: dyslipidemia; atherosclerosis; oxidative stress; cardioprotection; type 2 diabetes; bioactive compounds; chronic diseases; nutraceuticals

Special Issue Information

Dear Colleagues,

Metabolic Syndrome and Type 2 Diabetes are the major causes of morbidity and mortality in the elderly, with an increasing prevalence worldwide. These disorders cause micro-and macrovascular damage, leading to consequences, such as CAD, ischemia, heart failure, stroke, neuronal disturbances, reproductive and joint diseases, and other syndromes characterized by dysregulated inflammatory processes, and degradation of tissue function. Despite numerous recommendations emphasizing lifestyle changes, pharmacotherapy is also essential in the prevention and treatment of these syndromes, especially in more severe or chronic cases.

Bioactive compounds (phytonutrients or functional foods) have been defined as the extra nutritional constituents that are derived from natural products in small quantities. These molecules are mainly phytochemicals that can modulate metabolic processes, resulting in the promotion of better health. The bioaccessibility and bioavailability of each bioactive compound differs greatly, since several bioactive plant compounds are produced as secondary metabolites that are not essential for the daily functioning of the plant (such as growth), but play a significant role in competition, defense, attraction and signaling. Bioactive compounds in the plants can be specified as secondary plant metabolites eliciting pharmacological or toxicological effects in humans and animals. They include various molecules such as flavonoids, carotenoids, carnitine, choline, coenzyme Q, creatine, dithiolthiones, phytosterols, polysaccharides, phytoestrogens, glucosinolates, polyphenols, anthocyanins, prebiotics, and taurine.

This special issue aims to bring together food chemistry, food technology (with analysis or characterization of natural compounds) in medical interest and nutraceutical researches (for diet therapy and cosmetics) to identify and discuss cutting-edge research on novel ways in the treatment of Metabolic Syndrome and Type 2 Diabetes.

Dr. Béla Juhász
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • Metabolic Syndrome
  • Diabetes
  • Cardiovascular Diseases
  • Obesity
  • Insulin Resistance
  • Dyslipidemia
  • Inflammation
  • Bioactive Compounds
  • Nutraceuticals
  • Natural Products
  • Food Chemistry

Published Papers (1 paper)

View options order results:
result details:
Displaying articles 1-1
Export citation of selected articles as:


Open AccessArticle Hexanoic, Octanoic and Decanoic Acids Promote Basal and Insulin-Induced Phosphorylation of the Akt-mTOR Axis and a Balanced Lipid Metabolism in the HepG2 Hepatoma Cell Line
Molecules 2018, 23(9), 2315; https://doi.org/10.3390/molecules23092315
Received: 7 August 2018 / Revised: 6 September 2018 / Accepted: 8 September 2018 / Published: 11 September 2018
PDF Full-text (2102 KB) | HTML Full-text | XML Full-text | Supplementary Files
Metabolic illnesses such as non-alcoholic fatty liver disease (NAFLD) are in constant increase worldwide. Highly consumed long chain fatty acids (LCFA) are among the most obesogenic and steatogenic nutrients. Hepatic steatosis is associated with several complications such as insulin resistance. Growing evidence points
[...] Read more.
Metabolic illnesses such as non-alcoholic fatty liver disease (NAFLD) are in constant increase worldwide. Highly consumed long chain fatty acids (LCFA) are among the most obesogenic and steatogenic nutrients. Hepatic steatosis is associated with several complications such as insulin resistance. Growing evidence points to medium chain fatty acids (MCFA), more efficiently oxidized than LCFA, as a promising dietary alternative against NAFLD. However, reports on the hepatic effects of MCFA are sometimes conflicting. In this study we exposed HepG2 cells, a human hepatocellular model, to 0.25 mM of hexanoic (C6), or octanoic (C8), and decanoic (C10) acids separately or in a C8 + C10 equimolar mix reflecting commercially available MCFA-rich oils. We found that C6, a poorly studied MCFA, as well as C8 and C10 did not provoke the deleterious lipid anabolism runaway typically induced by LCFA palmitate. MCFA tended, instead, to promote a balanced metabolic profile and were generally non-cytotoxic. Accordingly, mitochondrial integrity was mostly preserved following MCFA treatment. However, treatments with C8 induced a mitochondrial membrane potential decrease, suggesting prolonged exposure to this lipid could be problematic. Finally, MCFA treatments maintained optimal insulin sensitivity and even fostered basal and insulin-dependent phosphorylation of the Akt-mTOR pathway. Overall, MCFA could constitute an effective nutritional tool to manage liver steatosis and hepatic insulin resistance. Full article
(This article belongs to the Special Issue Bioactive Compounds for Metabolic Syndrome and Type 2 Diabetes-II)

Figure 1

Back to Top